Issue Date: May 16, 1996
Issued by: Center for Biologics Evaluation and Research
Topic(s): Blood, Blood Products
Status: Final
Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV): Memorandum to Registered Blood and Plasma Establishments
In a public meeting of the Blood Products Advisory Committee (BPAC) on March 21, 1996, after review and discussion of the relevant information available, concern was expressed that the use of a supplemental test for anti-HCV that uses fewer antigens than the screening test for anti-HCV may cause uncertainties. In particular, the Committee discussed its concern that the use of the Chiron RIBA HCV 2.0 Immunoblot Assay (SIA) as a supplemental test for anti-HCV should not be used for donor re-entry if the Ortho™ HCV Version 3.0 ELISA Test System was used as a screening test. FDA has considered the BPAC concerns and sets forth in the attached recommendations donor re-entry and counseling procedures that should be used in this situation.
Download the Guidance Document
